You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2024

Claims for Patent: 8,829,165

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,829,165

Title:	Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
Abstract:	Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
Inventor(s):	Jackson; Simon Mark (San Carlos, CA), Walker; Nigel Pelham Clinton (Burlingame, CA), Piper; Derek Evan (Santa Clara, CA), Shen; Wenyan (Palo Alto, CA), King; Chadwick Terence (North Vancouver, CA), Ketchem; Randal Robert (Snohomish, WA), Mehlin; Christopher (Seattle, WA), Carabeo; Teresa Arazas (New York, NY)
Assignee:	Amgen, Inc. (Thousand Oaks, CA)
Application Number:	13/860,016
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,829,165
Patent Claims:	1. An isolated monoclonal antibody, wherein, when bound to PCSK9, the monoclonal antibody binds to at least one of the following residues: S153, I154, P155, R194, D238, A239, I369, S372, D374, C375, T377, C378, F379, V380, or S381 of SEQ ID NO:3, and wherein the monoclonal antibody blocks binding of PCSK9 to LDLR. 2. The isolated monoclonal antibody of claim 1, wherein the monoclonal antibody binds to at least S153. 3. The isolated monoclonal antibody of claim 1, wherein the monoclonal antibody binds to at least I154. 4. The isolated monoclonal antibody of claim 1, wherein the monoclonal antibody binds to at least P155. 5. The isolated monoclonal antibody of claim 1, wherein the monoclonal antibody binds to at least T377. 6. The isolated monoclonal antibody of claim 1, wherein the monoclonal antibody binds to at least R194. 7. The isolated monoclonal antibody of claim 1, wherein the monoclonal antibody binds to at least D238. 8. The isolated monoclonal antibody of claim 1, wherein the monoclonal antibody binds to at least A239. 9. The isolated monoclonal antibody of claim 1, wherein the monoclonal antibody binds to at least I369. 10. The isolated monoclonal antibody of claim 1, wherein the monoclonal antibody binds to at least S372. 11. The isolated monoclonal antibody of claim 1, wherein the monoclonal antibody binds to at least D374. 12. The isolated monoclonal antibody of claim 1, wherein the monoclonal antibody binds to at least C375. 13. The isolated monoclonal antibody of claim 1, wherein the monoclonal antibody binds to at least C378. 14. The isolated monoclonal antibody of claim 1, wherein the monoclonal antibody binds to at least F379. 15. The isolated monoclonal antibody of claim 1, wherein the monoclonal antibody binds to at least V380. 16. The isolated monoclonal antibody of claim 1, wherein the monoclonal antibody binds to at least S381. 17. A pharmaceutical composition comprising an isolated monoclonal antibody, wherein, when bound to PCSK9, the isolated monoclonal antibody binds to at least one of the following residues: S153, I154, P155, R194, D238, A239, I369, S372, D374, C375, T377, C378, F379, V380, or S381 of SEQ ID NO:3, and wherein the monoclonal antibody blocks binding of PCSK9 to LDLR. 18. The isolated monoclonal antibody of claim 1 wherein the isolated monoclonal antibody blocks the binding of PCSK9 to LDLR by at least 80%. 19. The isolated monoclonal antibody of claim 1 wherein the isolated monoclonal antibody binds to at least two of the following residues S153, I154, P155, R194, D238, A239, I369, S372, D374, C375, T377, C378, F379, V380, or S381 of PCSK9 listed in SEQ ID NO:3. 20. The isolated monoclonal antibody of claim 1 wherein the isolated monoclonal antibody binds to at least four of the following residues S153, I154, P155, R194, D238, A239, I369, S372, D374, C375, T377, C378, F379, V380, or S381 of PCSK9 listed in SEQ ID NO:3. 21. The isolated monoclonal antibody of claim 1 wherein the isolated monoclonal antibody is a human antibody. 22. The isolated monoclonal antibody of claim 1 wherein the isolated monoclonal antibody is a humanized antibody. 23. The isolated monoclonal antibody of claim 1 wherein the isolated monoclonal antibody binds to at least two of the following residues S153, I154, P155, R194, D238, A239, I369, S372, D374, C375, T377, C378, F379, V380, or S381 of PCSK9 listed in SEQ ID NO:3 and blocks the binding of PCSK9 to LDLR by at least 80%. 24. The isolated monoclonal antibody of claim 23 wherein the isolated monoclonal antibody is a human antibody. 25. The isolated monoclonal antibody of claim 23 wherein the isolated monoclonal antibody is a humanized antibody. 26. The isolated monoclonal antibody of claim 1 wherein the isolated monoclonal antibody binds to at least four of the following residues S153, I154, P155, R194, D238, A239, I369, S372, D374, C375, T377, C378, F379, V380, or S381 of PCSK9 listed in SEQ ID NO:3 and blocks the binding of PCSK9 to LDLR by at least 80%. 27. The isolated monoclonal antibody of claim 26 wherein the isolated monoclonal antibody is a human antibody. 28. The isolated monoclonal antibody of claim 26 wherein the isolated monoclonal antibody is a humanized antibody. 29. A pharmaceutical composition comprising an isolated monoclonal antibody, wherein the isolated monoclonal antibody binds to at least two of the following residues S153, I154, P155, R194, D238, A239, I369, S372, D374, C375, T377, C378, F379, V380, or S381 of PCSK9 listed in SEQ ID NO:3 and blocks the binding of PCSK9 to LDLR by at least 80%.

Details for Patent 8,829,165

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen Inc.	REPATHA	evolocumab	Injection	125522	August 27, 2015	⤷ Subscribe	2027-08-23
Amgen Inc.	REPATHA	evolocumab	Injection	125522	July 08, 2016	⤷ Subscribe	2027-08-23
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 8,829,165

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2009026558	⤷ Subscribe
United States of America	9920134	⤷ Subscribe
United States of America	9493576	⤷ Subscribe
United States of America	9056915	⤷ Subscribe
United States of America	9045547	⤷ Subscribe
United States of America	8981064	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.